NVO - Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns | Benzinga
Novo Nordisk A/S (NYSE:NVO) has encountered manufacturing challenges and drug shortages for its diabetes and weight loss drugs due to unprecedented demand for Wegvoy and Ozempic.
To manage the shortage, Novo Nordisk agreed to acquire three fill-finish sites from Novo Holdings A/S in connection with a transaction where Monday, Novo Holdings agreed to acquire Catalent Inc (NYSE:CTLT).
Novo Nordisk will acquire the three manufacturing sites for an upfront payment of $11 billion.
The three manufacturing sites specialize in the sterile filling of drugs and are located in Anagni (Italy), Brussels (Belgium), and Bloomington (Indiana, US).
The three sites employ more than 3,000 people and have ...